Altum Sequencing

🧬 Liquid Biopsy: Where Can We Find It?  Liquid biopsy refers to the analysis of tumor-derived material in body fluids. While blood is the most widely studied source, it is not the only one. Depending on the tumor type and its location, other fluids can provide valuable molecular information. 🔹 Plasma (blood): the gold standard for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes.  🔹 Urine: particularly useful for bladder cancer, kidney cancer, and some systemic malignancies.  🔹 Saliva: explored in head and neck tumors for detecting DNA fragments shed locally.  🔹 Cerebrospinal fluid (CSF): a key source in brain tumors, where standard biopsies are often too risky or impossible. Each fluid offers different insights, and together they expand the possibilities of real-time cancer monitoring beyond traditional tissue biopsies. At Altum Sequencing, we focus on blood-derived ctDNA for Minimal Residual Disease (MRD) monitoring, since it offers the highest sensitivity and broadest clinical applicability. By analyzing plasma samples, we aim to provide doctors with reliable tools that can be repeated over time — making cancer follow-up both precise and patient-friendly. #AltumSequencing #HuntingCancer #LiquidBiopsy #PrecisionMedicine #OncologyInnovation #CancerDetection 

🤝 Innovation Meets Collaboration in Healthcare Yesterday, Altum Sequencing took part in two outstanding initiatives in Barcelona, both focused on strengthening the connection between startups, investors, and the healthcare ecosystem. 🍽️ Meet & Lunch by Fenin, Federación Española de Empresas de Tecnología Sanitaria. A unique space for open discussion and exchange of experiences between health tech entrepreneurs and investors. Conversations centered around how to foster innovation responsibly, share lessons learned, and promote collaboration models that accelerate access to new technologies for patients. 🏥 Barcelona Health Expo – NextGen Health, organized by Plug and Play Tech Center and Hospital de la Santa Creu i Sant Pau. An inspiring event highlighting the importance of trust-based collaboration between hospitals, startups, and corporations. Discussions reflected a shared vision: innovation in healthcare must be both transformative and human-centered, ensuring real benefits for patients and professionals alike. 💡 These encounters reinforce our conviction that progress in healthcare depends on building bridges between science, technology, and collaboration. We extend our thanks to Fenin, Plug and Play Tech Center, Hospital Sant Pau, and all participants who continue to make innovation possible through cooperation and shared vision. #AltumSequencing #HuntingCancer #HealthTech #Innovation #Collaboration #DigitalHealth

🧬 Precision Medicine: Transforming Cancer Care #Cancer is not a single disease — it’s a collection of many subtypes, each defined by unique genetic and molecular characteristics. In the past, #lungcancer or #lymphoma were broad labels. Today, thanks to advances in genomics and molecular profiling, we know that each has dozens of subtypes, each requiring a different therapeutic approach. 🔎 From Diagnosis to Follow-Up  Precision medicine starts by dissecting the tumor: analyzing proteins on the cell surface, mapping genetic alterations, and identifying mutations that drive disease. This enables doctors to select the most effective treatments and predict how each patient will respond.    But the process doesn’t stop at diagnosis. Continuous monitoring — even after treatment — is essential. Detecting whether a patient is truly in remission, or if relapse is starting at the molecular level, is key to adapting therapy and avoiding unnecessary toxicity. 💉 The Role of #Liquid Biopsy  Beyond traditional biopsies, liquid biopsy allows us to detect tumor DNA fragments or cells circulating in blood and other fluids. With ultra-sensitive tools, doctors can now identify one tumor cell among a million healthy ones — making it possible to anticipate relapses earlier and personalize treatment strategies with unmatched precision. 🌍 Altum’s Mission  At Altum Sequencing, we bring precision medicine to life through our ultra-sensitive ctDNA-based MRD technology. By combining next-generation sequencing and advanced analytics, we help clinicians detect relapse earlier, guide treatment intensity, and ultimately improve patient outcomes. #AltumSequencing #HuntingCancer #PrecisionMedicine #LiquidBiopsy Joaquin Martinez César Velasco Muñoz AstraZeneca

🎓 Building bridges between academia and industry. Yesterday, Altum Sequencing joined Universidad CEU San Pablo to inaugurate Aulas CEU-Empresa program — an initiative designed to strengthen collaboration between universities and companies, connecting education, innovation, and employability. Through this partnership, we aim to bring the reality of biotechnology closer to students — fostering talent, encouraging innovation, and helping the next generation of professionals take their first steps into the world of precision medicine and genomics. 🤝 We’re proud to contribute to this inspiring ecosystem that unites research, technology, and education to build the future of science together. A heartfelt thanks to Universidad CEU San Pablo, its Rector Rosa Visiedo Claverol, the Dean of the Faculty Tomás Chivato, the Director of the Genetics Degree Alejandra Cruz Varona, the Director of the Bioinformatics and Big Data Degree Osvaldo Graña Castro, Laura Martín and Maider Uriarte Olandia, from Professional Careers, and the entire team for the warm welcome and commitment to innovation. #AltumSequencing #HuntingCancer #Innovation #PrecisionMedicine #Education #CEU

🚀 Wrapping up an incredible 2-Days at Valencia Digital Summit 2025! These past days at VDS have been full of inspiration, innovation, and meaningful connections. We’ve met amazing people, shared ideas with startups, corporates, and investors, and had truly fruitful conversations about how technology can transform healthcare. 💡 🎤 Altum Sequencing took the stage twice! Our CEO Marina Planas pitched at: 🔹 The VDS Scaleup Pitch Competition, where we proudly represented one of the Top 10 companies selected from over 1,200 applications. 🔹 The SantanderX Scaleup Pitch Competition, standing among the Top 10 international scaleups chosen from more than 500 contenders. 🧬 At Altum, we’re redefining how cancer is monitored and managed — using liquid biopsy and next-generation sequencing (NGS) to detect minimal residual disease (MRD) with unmatched sensitivity and precision. 🙏 A heartfelt thank you to VDS, Startup Valencia and SantanderX for this opportunity and recognition. Thanks for all our interesting conversations with CaixaBank, IBM, Natalia Olson-Urtecho, Inclimo Climate Tech Fund, LUMO Labs, Zubi Capital and many others driving collaboration across innovation and healthcare. 📩 Let’s keep the conversation going! If you want to discover how our technology can revolutionize cancer monitoring and precision medicine, reach out — we’d love to connect. See you next year in Valencia! 💙 #AltumSequencing #HuntingCancer #VDS2025 #SantanderX #StartupValencia #PrecisionMedicine #LiquidBiopsy

🎗️ International Breast Cancer Day | October 19 Breast cancer is the most frequently diagnosed cancer in women worldwide —representing 1 in every 4 female cancers. Each year, over 2.3 million women receive this diagnosis.  It remains the leading cause of cancer death among women globally.  And worryingly, incidence is rising — especially among younger patients. 📉 The Clinical Challenge Even with major advances in surgery, radiotherapy, and systemic treatments,  up to 40% of patients relapse after initial therapy. Why? Because current monitoring methods — imaging and serum biomarkers — often miss Minimal Residual Disease (MRD) until it’s too late.  By the time recurrence is visible, intervention is much harder. 🧬 Our Contribution On a day like today, we invite you to read a study led by Iñaki Comino-Méndez (IBIMA) and Angel Guerrero-Zotano - Fundación Instituto Valenciano de Oncología (IVO), which validated our ultrasensitive ctDNA test for detecting MRD in breast cancer patients. Our patient-specific test demonstrated that can detect tumor DNA up to 5.7 years before clinical relapse. This approach: ✨ Predicts relapse with unprecedented accuracy.  🩸 Enables non-invasive monitoring through liquid biopsy.  🧬 Supports oncologists in tailoring truly personalized treatments. Integrating genomic sequencing and liquid biopsy can shift breast cancer care—from reactive treatment to proactive, precision medicine Do you work in breast cancer and would like to learn more about our technology? Don't hesitate to contact us: [email protected] 👉 Read the full publication here: https://lnkd.in/dzxDBwTj #AltumSequencing #HuntingCancer #BreastCancer #LiquidBiopsy #PrecisionMedicine #InternationalBreastCancerDay